Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease in Japan

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease in Japan — alphai